Real-World Outcomes in Diabetic Macular Edema for the 0.2 μg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK
Bushra Mushtaq,1 Ajay Bhatnagar,2 Helen Palmer3 1Birmingham Midland Eye Centre, City Hospital SWBH NHS Trust, Birmingham, UK; 2Department of Ophthalmology, New Cross Hospital, The Royal Wolverhampton NHS Trust, Wolverhampton, UK; 3Ophthalmology Department, Queen Elizabeth Hospital Birmingham, Univer...
Main Authors: | Mushtaq B, Bhatnagar A, Palmer H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-07-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/real-world-outcomes-in-diabetic-macular-edema-for-the-02-gday-fluocino-peer-reviewed-fulltext-article-OPTH |
Similar Items
-
Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
by: Adán A, et al.
Published: (2020-07-01) -
Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)
by: McCluskey JD, et al.
Published: (2019-04-01) -
Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
by: William Fusi-Rubiano, et al.
Published: (2018-09-01) -
Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
by: Saedon H, et al.
Published: (2017-03-01) -
Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes
by: Alberto La Mantia, et al.
Published: (2018-12-01)